---

$0.27

+0.0081 ( +3.09% ) 240.7K

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-09-27	Buy	588235.00	Moran James P
2024-08-12	Sale	-200000.00	PRINS RICHARD K
2024-05-13	Sale	-8823529.00	Bradbury Strategic Investment Fund A (Cayman Islands Registration No. CR-359857)
2024-03-18	Sale	-333333.00	MUKUNDA RAM
2024-03-15	Sale	-150000.00	LIERMAN TERRY L
2024-03-15	Sale	-50000.00	Moran James P
2024-03-15	Sale	-100000.00	PRINS RICHARD K
2024-03-15	Sale	-83333.00	GRIMALDI CLAUDIA